Answers are grounded in this paper and cite their sources.
Xenotransplantation, the transplantation of organs or tissues between different species, has emerged as a potential solution to address the organ shortage. Introduction of genetically modified pigs with knockout of known xeno-antigens and addition of human complement and coagulation pathway regulatory proteins as well as anti-inflammatory and human ‘self-recognition’ molecules has enabled significant progress particularly for heart and kidney xenografts. Lung xenotransplantation presents unique challenges due to the lung’s complex anatomic structure and associated immunological landscape: a very large surface-area interface between blood and the external environment is defended by an array of innate and adaptive immunocytes. Although recipient survival of up to 31 days has been achieved, formidable obstacles still need to be addressed before clinical lung xenograft application can be attempted with reasonable prospects for therapeutic efficacy. Nonetheless, lung xenotransplantation holds great potential as a future alternative for patients with end-stage lung disease, and ongoing research efforts continue to pave the way for its translation into clinical practice.
No takes yet. Share an insight, caveat, or question.
Chaban et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: